

Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Description

NEW YORK, June 9, 2020 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.

[Relmada Therapeutics Corporate Logo](#)

<u>Fireside Chat Details:</u>		
Date:		Thursday, June 11, 2020
Time:		3:00 PM EDT
Webcast:		A live webcast of the fireside chat will be available by visiting the “Investors” section of the company’s website: www.relmada.com . A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada’s lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

For Media Inquiries:
FischTank PR
relmada@fischtankpr.com

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-301072754.html>

SOURCE Relmada Therapeutics, Inc.

Released June 9, 2020

Date Created
2020/06/09